Biocon shares end over 2 pc higher

Shares of biopharmaceutical firm Biocon today ended over 2 per cent higher after the company said its Malaysian subsidiary has received EU GMP compliance certificate from the Health Products Regulatory Authority of Ireland for its insulin manufacturing facility.
The stock ended the day at Rs 342.40, up 2.16 per cent on BSE. During the day, it gained 5.32 per cent to Rs 353.
At NSE, shares of the company jumped 2.3 per cent to close at Rs 342.45.
The company's market valuation rose by Rs 435 crore to Rs 20,544 crore.
In terms of equity volume, 4.81 lakh shares of the company were traded on BSE and over 61 lakh shares changed hands at NSE during the day.

"Biocon's subsidiary in Malaysia, Biocon Sdn Bhd, has been issued a certificate of 'GMP compliance' for its insulin manufacturing facility by HPRA (Ireland) as the representative European inspection authority," Biocon spokesperson said in a statement yesterday.
The certificate reflects that the agency considered the plant to be in compliance with principles and guidelines of good manufacturing practices for active substances, sterile drug products and quality control testing operations, the statement added.
Biocon's Malaysia facility was inspected by the European Medicines Agency (EMA) in April 2017.